Abstract
Many therapies in clinical trials are based on single drug-single target relationships. To further extend this concept to multi-target approaches using multi-targeted drugs, we developed a machine learning pipeline to unravel the target landscape of kinase inhibitors. This pipeline, which we call 3D-KINEssence, uses a new type of protein fingerprints (3D FP) based on the structure of kinases generated through a 3D convolutional neural network (3D-CNN). These 3D-CNN kinase fingerprints were matched to molecular Morgan fingerprints to predict the targets of each respective kinase inhibitor based on available bioactivity data. The performance of the pipeline was evaluated on two test sets: a sparse drug-target set where each drug is matched in most cases to a single target and also on a densely-covered drug-target set where each drug is matched to most if not all targets. This latter set is more challenging to train, given its non-exclusive character. Our model’s root-mean-square error (RMSE) based on the two datasets was 0.68 and 0.8, respectively. These results indicate that 3D FP can predict the target landscape of kinase inhibitors at around 0.8 log units of bioactivity. Our strategy can be utilized in proteochemometric or chemogenomic workflows by consolidating the target landscape of kinase inhibitors.
Funder
Amsterdam Data Science
Brain Tumour Charity
Innovation Exchange Amsterdam (IXA) grant
Amsterdam University Medical Centers
Publisher
Public Library of Science (PLoS)
Subject
Computational Theory and Mathematics,Cellular and Molecular Neuroscience,Genetics,Molecular Biology,Ecology,Modeling and Simulation,Ecology, Evolution, Behavior and Systematics
Reference89 articles.
1. Structural Chemogenomics: Profiling Protein–Ligand Interactions in Polypharmacological Space.;B Briels;Structural Biology in Drug Discovery: Methods, Techniques, and Practices.,2020
2. Overall survival in patients with pancreatic cancer receiving matched therapies following molecular profiling: a retrospective analysis of the Know Your Tumor registry trial;MJ Pishvaian;The Lancet Oncology,2020
3. The Drug Rediscovery protocol facilitates the expanded use of existing anticancer drugs;D Van der Velden;Nature,2019
4. A convergence-based framework for cancer drug resistance;DJ Konieczkowski;Cancer Cell,2018
5. The TICking clock of EGFR therapy resistance in glioblastoma: Target Independence or target Compensation;H Saleem;Drug Resist Updat,2019
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献